查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1889196

全球组织工程和再生医学市场：预测（至2032年）－按产品、材料类型、治疗方法、服务模式、应用、最终用户和地区进行分析

Tissue Engineering and Regeneration Market Forecasts to 2032 - Global Analysis By Product, Material Type, Therapy Approaches, Service Models, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2025 年，全球组织工程和再生医学市场规模将达到 399.4 亿美元，到 2032 年将达到 1,333.9 亿美元，预测期内复合年增长率为 18.8%。

组织工程和再生医学是指利用功能性生物材料修復、替代和改善受损组织和器官的功能。该领域结合了生物材料、治疗性细胞和讯号分子，以引导自然再生并恢復组织结构和功能。它融合了工程和生物学，专注于设计支架、支持细胞活性和促进组织修復。其应用范围广泛，涵盖创伤护理、骨骼和软骨修復、牙齿修復、心臟组织再生和器官重组等领域，旨在满足自然癒合过程无法满足的医疗需求。

据全球类风湿关节炎网络称，关节炎影响着全球超过 3.5 亿人，预计到 2040 年，约有 7,800 万美国成年人将患上这种疾病。

慢性病发生率呈上升趋势

糖尿病、心血管疾病和肌肉骨骼疾病等慢性病的日益增多，显着推动了对先进组织工程解决方案的需求。这些疾病往往会导致组织损伤和器官衰竭，加速了再生医学的发展。人口老化进一步加剧了退化性疾病的盛行率，并推动了工程组织的广泛应用。因此，再生医学正成为现代医疗保健的关键组成部分。日益加重的疾病负担是推动市场扩张的强劲动力。

复杂且不明确的调控通路

企业往往难以满足生物材料、工程组织、复合材料产品等多种产品的核准标准。冗长的临床检验流程进一步延缓了商业化。监管的不确定性增加了合规成本，并延迟了创新治疗方法的市场准入。为了避免延误，研发人员必须在文件编制、品质系统和监管咨询方面投入大量资金。这些挑战可能会限制产品上市，并抑制更广泛的市场成长。

发挥3D生物列印的潜力

列印技术的进步使得对细胞定位、支架结构和材料成分的控制更加精准。这些创新促进了用于移植和药物测试的功能性组织的开发，同时也有助于加快原型製作速度，缩短再生医学产品的研发週期。 3D生物列印技术的广泛应用正在推动生物技术公司、研究机构和材料开发商之间的合作。其不断成长的潜力使其成为市场的重要成长引擎。

报销政策分散或不完善

许多治疗方法属于新兴或未定义类别，导致保险覆盖范围难以预测。有限的保险支持阻碍了医疗机构和患者采用再生疗法。评估标准的差异也使得生产商难以证明其成本效益。这些挑战延缓了临床应用，并阻碍了大规模商业化。如果没有更健全的报销机制，市场发展可能会受到限制。

新冠疫情的感染疾病：

疫情初期扰乱了供应链，推迟了择期手术，并影响了对组织工程产品的需求。多家机构的研究被迫暂停，导致创新週期放缓。然而，新冠肺炎疫情凸显了先进生物材料和再生医学工具在治疗和復健中的重要性。这场危机加速了政府和私人对生物医学研究的投资。疫情后的復苏重新燃起了人们对利用再生医学治疗慢性疾病的兴趣。

预测期内，支架和生物材料领域将占据最大的市场份额。

由于支架和生物材料在组织工程过程中发挥基础性作用，预计在预测期内，它们将占据最大的市场份额。这些构建模组为细胞黏附和组织形成提供了必要的结构支撑。可生物降解聚合物、水凝胶和生物活性材料的创新正在拓展其应用范围。它们在研究、临床试验和商业性治疗中的广泛应用，正在巩固该领域的市场地位。对可客製化和生物相容性材料的日益增长的需求，也进一步推动了市场需求。

预测期内，生技公司板块的复合年增长率将最高。

由于再生医学领域研发的快速发展，预计生技公司板块在预测期内将达到最高成长率。对新型生物材料、细胞疗法和工程组织的重点关注正在推动创新加速。许多公司正与医院和学术机构建立策略合作伙伴关係，以扩大突破性成果。不断成长的创业投资资金正在助力公司拓展临床试验和商业化进程。这些公司也积极采用3D生物列印和干细胞工程等最尖端科技。

占比最大的地区：

预计北美将在预测期内占据最大的市场份额，这主要得益于其强大的医疗保健基础设施和较高的技术普及率。该地区受益于充足的研究经费和顶尖大学的积极参与。支持再生医学的法规结构进一步促进了产品开发。美国和加拿大慢性病发病率的上升推动了对先进组织治疗的需求。领先生物技术公司的存在增强了创新和商业化生态系统。

年复合成长率最高的地区：

预计亚太地区在预测期内将实现最高的复合年增长率，这主要得益于医疗保健投资的成长和生物医学研究的进步。中国、日本和印度等国家正迅速采用再生医学技术。政府为促进生物技术和组织工程而采取的措施正在加速市场渗透。慢性病和退化性疾病患者数量的增加，催生了对先进治疗方法的强劲需求。全球企业与区域机构之间日益密切的合作也推动了相关领域的发展。

免费客製化服务：

订阅本报告的用户可从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 引言

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
  • 分析材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球组织工程和再生医学市场（按产品划分）

  • 支架和生物材料
  • 细胞和细胞库
  • 生物墨水和耗材
  • 生物反应器和培养系统
  • 诊断和监测工具
  • CDMO/契约製造服务
  • 其他产品

6. 全球组织工程和再生医学市场（按材料类型划分）

  • 天然聚合物
  • 合成聚合物
  • 陶瓷和生物活性玻璃
  • 复合材料
  • 水凝胶/细胞外基质模拟物

7. 全球组织工程与再生医学市场（依治疗方法划分）

  • 基于细胞疗法
  • 支架引导
  • 无细胞生技药品/分泌体
  • 复合材料
  • 合成组织替代品

8. 全球组织工程及再生医学市场依服务模式划分

  • 现成产品
  • 个体化/自体疗法
  • 合约开发和製造
  • 研究服务和许可

9. 全球组织工程和再生医学市场（按应用划分）

  • 整形外科
  • 心血管系统
  • 皮肤/创伤治疗
  • 神经
  • 眼科
  • 泌尿系统和肾臟病学
  • 消化系统和肝臟
  • 口腔颚颜面外科
  • 耳鼻喉科和整形外科

第十章 全球组织工程与再生医学市场（依最终使用者划分）

  • 医院及手术中心
  • 研究和学术机构
  • 生物技术和製药公司
  • CRO/CDMO
  • 诊断检查室
  • 其他最终用户

第十一章 全球组织工程与再生医学市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十三章：企业概况

  • Organogenesis
  • Mesoblast Limited
  • Stryker Corporation
  • CollPlant Biotechnologies
  • Integra LifeSciences
  • Baxter International
  • Medtronic plc
  • Merck KGaA
  • Zimmer Biomet
  • Corning Incorporated
  • BICO
  • Lonza Group
  • Organovo Holdings
  • 3M Company
  • Tissue Regenix
Product Code: SMRC32656

According to Stratistics MRC, the Global Tissue Engineering and Regeneration Market is accounted for $39.94 billion in 2025 and is expected to reach $133.39 billion by 2032 growing at a CAGR of 18.8% during the forecast period. Tissue engineering and regeneration refer to creating functional biological materials that help repair, replace, or enhance injured tissues and organs. The discipline merges biomaterials, therapeutic cells, and signaling molecules to guide natural regeneration and rebuild structure and function. Using engineering and biological science, it focuses on designing scaffolds, supporting cell activity, and driving tissue restoration. Its use extends across wound care, bone and cartilage repair, dental restoration, heart tissue regeneration, and organ reconstruction, addressing medical needs unmet by natural healing processes.

According to the Global RA Network, arthritis affects over 350 million people worldwide, and projections suggest that by 2040, approximately 78 million U.S. adults will suffer from the condition.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The rising incidence of chronic illnesses such as diabetes, cardiovascular disorders, and musculoskeletal conditions is significantly increasing the need for advanced tissue engineering solutions. These diseases often lead to tissue damage or organ failure, intensifying demand for regenerative therapies. Growing aging populations further amplify the prevalence of degenerative disorders, supporting wider adoption of engineered tissues. As a result, regenerative medicine is becoming a central component of modern healthcare pathways. This accelerating disease burden serves as a strong catalyst for market expansion.

Restraint:

Complex and unclear regulatory pathways

Companies often struggle to meet diverse approval standards for biomaterials, engineered tissues, and combination products. Lengthy clinical validation processes further slow commercialization efforts. Regulatory ambiguity increases compliance costs and delays market entry for innovative therapies. Developers must invest heavily in documentation, quality systems, and regulatory consultations to avoid setbacks. These challenges can restrict product launches and limit broader market growth.

Opportunity:

Harnessing the potential of 3D bioprinting

Advances in printing technologies allow improved control over cell placement, scaffold architecture, and material composition. This innovation enhances the development of functional tissues for transplantation and drug testing. The technique also supports faster prototyping, reducing development timelines for regenerative products. As 3D bioprinting becomes more accessible, it is driving collaborations between biotech firms, research institutes, and material developers. Its expanding potential positions it as a major growth engine for the market.

Threat:

Fragmented or inadequate reimbursement policies

Many therapies fall under emerging or undefined categories, making coverage decisions unpredictable. Limited insurance support discourages both clinics and patients from choosing regenerative treatments. Manufacturers face difficulties demonstrating cost-effectiveness due to varying evaluation criteria. These gaps slow down clinical uptake and hinder large-scale commercialization. Without stronger reimbursement structures, market progression may remain constrained.

Covid-19 Impact:

The pandemic initially disrupted supply chains and delayed elective procedures, affecting demand for tissue-engineered products. Research activities in several institutions were temporarily halted, slowing innovation cycles. However, Covid-19 highlighted the importance of advanced biomaterials and regenerative tools for healing and recovery. The crisis accelerated government and private investments in biomedical research. Post-pandemic rebuilding has driven renewed interest in regenerative medicine for chronic condition management.

The scaffolds & biomaterials segment is expected to be the largest during the forecast period

The scaffolds & biomaterials segment is expected to account for the largest market share during the forecast period, due to its foundational role in tissue engineering processes. These components provide essential structural support for cell attachment and tissue formation. Growing innovation in biodegradable polymers, hydrogels, and bioactive materials is expanding their application range. Their high usage in research, clinical studies, and commercial therapies strengthens the segment's market position. Increasing preference for customizable and biocompatible materials further drives demand.

The biotechnology companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biotechnology companies segment is predicted to witness the highest growth rate, as they rapidly advance R&D in regenerative therapies. Their strong focus on novel biomaterials, cell therapies, and engineered tissues fuels accelerated innovation. Many firms are entering strategic partnerships with hospitals and academic institutions to scale breakthroughs. Increased venture funding is enabling expansion into clinical trials and commercialization pathways. These companies are also adopting cutting-edge technologies such as 3D bioprinting and stem cell engineering.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to its strong healthcare infrastructure and high technological adoption. The region benefits from extensive research funding and active participation from leading universities. Regulatory frameworks supporting regenerative medicine further encourage product development. Rising chronic disease cases in the U.S. and Canada increase the need for advanced tissue therapies. Presence of major biotech companies strengthens the ecosystem for innovation and commercialization.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by growing healthcare investments and expanding biomedical research. Countries such as China, Japan, and India are rapidly adopting regenerative technologies. Government initiatives promoting biotechnology and tissue engineering are accelerating market penetration. Rising patient populations with chronic and degenerative conditions create strong demand for advanced therapies. Increasing collaborations between global players and regional institutes boost developmental activities.

Key players in the market

Some of the key players in Tissue Engineering and Regeneration Market include Organogen, Mesoblast, Stryker Co, CollPlant B, Integra Lif, Baxter Int, Medtronic, Merck KGa, Zimmer Bi, Corning In, BICO, Lonza Gro, Organovo, 3M Comp, and Tissue Re.

Key Developments:

In October 2025, Merck has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin in the US, to co-develop novel technologies that advance drug screening and discovery. The agreement unites Merck's strength in organoids and synthetic chemistry with Promega's market leading assay and reporter technologies. Together, the companies aim to develop assays capable of tracking cellular activity in real time using an innovative reporter system within three-dimensional (3D) cell cultures.

In December 2024, 3M and US Conec Ltd. announced a strategic licensing agreement for 3M(TM) Expanded Beam Optical Interconnect technology, a solution to meet the performance and scalability needs of next-generation data centers and advanced network architectures. The collaboration combines advanced optical technology from 3M with US Conec's expertise in high-density connectivity systems, expanded beam optics, and precision manufacturing to help deliver innovative solutions tailored to the evolving demands of modern networks.

Products Covered:

  • Scaffolds & Biomaterials
  • Cells & Cell Banks
  • Bio-inks & Consumables
  • Bioreactors & Culture Systems
  • Diagnostics & Monitoring Tools
  • CDMO / Contract Services
  • Other Products

Material Types Covered:

  • Natural Polymers
  • Synthetic Polymers
  • Ceramics & Bioactive Glasses
  • Composites
  • Hydrogels / ECM Mimetics

Therapy Approaches Covered:

  • Cell Therapy-Based
  • Scaffold-Guided
  • Acellular Biologics / Secretome
  • Combination Products
  • Synthetic Tissue Substitutes

Service Models Covered:

  • Off-the-Shelf Product
  • Personalized/autologous Therapies
  • Contract Development & Manufacturing
  • Research Services & Licensing

Applications Covered:

  • Orthopedic
  • Cardiovascular
  • Dermatology & Wound Healing
  • Neural
  • Ophthalmology
  • Urology & Nephrology
  • Gastrointestinal & Hepatic
  • Dental & Maxillofacial
  • ENT & Reconstructive

End Users Covered:

  • Hospitals & Surgical Centers
  • Research Institutes & Academia
  • Biotech & Pharma Companies
  • CROs / CDMOs
  • Diagnostic Labs
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Tissue Engineering and Regeneration Market, By Product

  • 5.1 Introduction
  • 5.2 Scaffolds & Biomaterials
  • 5.3 Cells & Cell Banks
  • 5.4 Bio-inks & Consumables
  • 5.5 Bioreactors & Culture Systems
  • 5.6 Diagnostics & Monitoring Tools
  • 5.7 CDMO / Contract Services
  • 5.8 Other Products

6 Global Tissue Engineering and Regeneration Market, By Material Type

  • 6.1 Introduction
  • 6.2 Natural Polymers
  • 6.3 Synthetic Polymers
  • 6.4 Ceramics & Bioactive Glasses
  • 6.5 Composites
  • 6.6 Hydrogels / ECM Mimetics

7 Global Tissue Engineering and Regeneration Market, By Therapy Approaches

  • 7.1 Introduction
  • 7.2 Cell Therapy-Based
  • 7.3 Scaffold-Guided
  • 7.4 Acellular Biologics / Secretome
  • 7.5 Combination Products
  • 7.6 Synthetic Tissue Substitutes

8 Global Tissue Engineering and Regeneration Market, By Service Models

  • 8.1 Introduction
  • 8.2 Off-the-Shelf Product
  • 8.3 Personalized/autologous Therapies
  • 8.4 Contract Development & Manufacturing
  • 8.5 Research Services & Licensing

9 Global Tissue Engineering and Regeneration Market, By Application

  • 9.1 Introduction
  • 9.2 Orthopedic
  • 9.3 Cardiovascular
  • 9.4 Dermatology & Wound Healing
  • 9.5 Neural
  • 9.6 Ophthalmology
  • 9.7 Urology & Nephrology
  • 9.8 Gastrointestinal & Hepatic
  • 9.9 Dental & Maxillofacial
  • 9.10 ENT & Reconstructive

10 Global Tissue Engineering and Regeneration Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & Surgical Centers
  • 10.3 Research Institutes & Academia
  • 10.4 Biotech & Pharma Companies
  • 10.5 CROs / CDMOs
  • 10.6 Diagnostic Labs
  • 10.7 Other End Users

11 Global Tissue Engineering and Regeneration Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Organogenesis
  • 13.2 Mesoblast Limited
  • 13.3 Stryker Corporation
  • 13.4 CollPlant Biotechnologies
  • 13.5 Integra LifeSciences
  • 13.6 Baxter International
  • 13.7 Medtronic plc
  • 13.8 Merck KGaA
  • 13.9 Zimmer Biomet
  • 13.10 Corning Incorporated
  • 13.11 BICO
  • 13.12 Lonza Group
  • 13.13 Organovo Holdings
  • 13.14 3M Company
  • 13.15 Tissue Regenix

List of Tables

  • Table 1 Global Tissue Engineering and Regeneration Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Tissue Engineering and Regeneration Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Tissue Engineering and Regeneration Market Outlook, By Scaffolds & Biomaterials (2024-2032) ($MN)
  • Table 4 Global Tissue Engineering and Regeneration Market Outlook, By Cells & Cell Banks (2024-2032) ($MN)
  • Table 5 Global Tissue Engineering and Regeneration Market Outlook, By Bio-inks & Consumables (2024-2032) ($MN)
  • Table 6 Global Tissue Engineering and Regeneration Market Outlook, By Bioreactors & Culture Systems (2024-2032) ($MN)
  • Table 7 Global Tissue Engineering and Regeneration Market Outlook, By Diagnostics & Monitoring Tools (2024-2032) ($MN)
  • Table 8 Global Tissue Engineering and Regeneration Market Outlook, By CDMO / Contract Services (2024-2032) ($MN)
  • Table 9 Global Tissue Engineering and Regeneration Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 10 Global Tissue Engineering and Regeneration Market Outlook, By Material Type (2024-2032) ($MN)
  • Table 11 Global Tissue Engineering and Regeneration Market Outlook, By Natural Polymers (2024-2032) ($MN)
  • Table 12 Global Tissue Engineering and Regeneration Market Outlook, By Synthetic Polymers (2024-2032) ($MN)
  • Table 13 Global Tissue Engineering and Regeneration Market Outlook, By Ceramics & Bioactive Glasses (2024-2032) ($MN)
  • Table 14 Global Tissue Engineering and Regeneration Market Outlook, By Composites (2024-2032) ($MN)
  • Table 15 Global Tissue Engineering and Regeneration Market Outlook, By Hydrogels / ECM Mimetics (2024-2032) ($MN)
  • Table 16 Global Tissue Engineering and Regeneration Market Outlook, By Therapy Approaches (2024-2032) ($MN)
  • Table 17 Global Tissue Engineering and Regeneration Market Outlook, By Cell Therapy-Based (2024-2032) ($MN)
  • Table 18 Global Tissue Engineering and Regeneration Market Outlook, By Scaffold-Guided (2024-2032) ($MN)
  • Table 19 Global Tissue Engineering and Regeneration Market Outlook, By Acellular Biologics / Secretome (2024-2032) ($MN)
  • Table 20 Global Tissue Engineering and Regeneration Market Outlook, By Combination Products (2024-2032) ($MN)
  • Table 21 Global Tissue Engineering and Regeneration Market Outlook, By Synthetic Tissue Substitutes (2024-2032) ($MN)
  • Table 22 Global Tissue Engineering and Regeneration Market Outlook, By Service Models (2024-2032) ($MN)
  • Table 23 Global Tissue Engineering and Regeneration Market Outlook, By Off-the-Shelf Product (2024-2032) ($MN)
  • Table 24 Global Tissue Engineering and Regeneration Market Outlook, By Personalized/autologous Therapies (2024-2032) ($MN)
  • Table 25 Global Tissue Engineering and Regeneration Market Outlook, By Contract Development & Manufacturing (2024-2032) ($MN)
  • Table 26 Global Tissue Engineering and Regeneration Market Outlook, By Research Services & Licensing (2024-2032) ($MN)
  • Table 27 Global Tissue Engineering and Regeneration Market Outlook, By Application (2024-2032) ($MN)
  • Table 28 Global Tissue Engineering and Regeneration Market Outlook, By Orthopedic (2024-2032) ($MN)
  • Table 29 Global Tissue Engineering and Regeneration Market Outlook, By Cardiovascular (2024-2032) ($MN)
  • Table 30 Global Tissue Engineering and Regeneration Market Outlook, By Dermatology & Wound Healing (2024-2032) ($MN)
  • Table 31 Global Tissue Engineering and Regeneration Market Outlook, By Neural (2024-2032) ($MN)
  • Table 32 Global Tissue Engineering and Regeneration Market Outlook, By Ophthalmology (2024-2032) ($MN)
  • Table 33 Global Tissue Engineering and Regeneration Market Outlook, By Urology & Nephrology (2024-2032) ($MN)
  • Table 34 Global Tissue Engineering and Regeneration Market Outlook, By Gastrointestinal & Hepatic (2024-2032) ($MN)
  • Table 35 Global Tissue Engineering and Regeneration Market Outlook, By Dental & Maxillofacial (2024-2032) ($MN)
  • Table 36 Global Tissue Engineering and Regeneration Market Outlook, By ENT & Reconstructive (2024-2032) ($MN)
  • Table 37 Global Tissue Engineering and Regeneration Market Outlook, By End User (2024-2032) ($MN)
  • Table 38 Global Tissue Engineering and Regeneration Market Outlook, By Hospitals & Surgical Centers (2024-2032) ($MN)
  • Table 39 Global Tissue Engineering and Regeneration Market Outlook, By Research Institutes & Academia (2024-2032) ($MN)
  • Table 40 Global Tissue Engineering and Regeneration Market Outlook, By Biotech & Pharma Companies (2024-2032) ($MN)
  • Table 41 Global Tissue Engineering and Regeneration Market Outlook, By CROs / CDMOs (2024-2032) ($MN)
  • Table 42 Global Tissue Engineering and Regeneration Market Outlook, By Diagnostic Labs (2024-2032) ($MN)
  • Table 43 Global Tissue Engineering and Regeneration Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.